Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > TIGIT class of checkpoint inhibitors fails with Keytruda

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 17, 2023 11:57am

149 Views

Post# 35345147

RE:TIGIT class of checkpoint inhibitors fails with Keytruda

In March last year Roche’s trial with their anti-TIGIT drug tiragolumab in small cell lung cancer (SCLC) also ended in failure.

Adding tiragolumab to checkpoint inhibitor Tecentriq and chemotherapy failed to improve progression-free survival in the study of 490 people undergoing first-line treatment for SCLC, causing the trial to miss one of its co-primary endpoints.

https://www.fiercebiotech.com/biotech/roches-lung-cancer-gamble-flames-out-tigit-digits-come-short-phase-3

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles